Skip to content
Medical Health Aged Care

IBMI SNQ and ICHOM Forms Strategic Partnership in Asia, Advancing Patient-centered Healthcare in the Region

The Institute for Biotechnology and Medicine Industry 2 mins read
TAIPEI, Taiwan--BUSINESS WIRE--

The Symbol of National Quality (SNQ), initiated by Taiwan’s Institute for Biotechnology and Medicine Industry (IBMI), has partnered with the International Consortium for Health Outcomes Measurement (ICHOM) to set a new benchmark for healthcare standards across the Asia-Pacific region.

The partnership agreement, signed by Chen Wei-Jao, Chief Convener, SNQ Committee, and Jennifer L. Bright, President and CEO of ICHOM, marked a significant collaboration between IBMI SNQ and ICHOM.

IBMI SNQ has implemented a rigorous three-stage review system that emphasizes structure, process, and outcomes in recognizing medical teams with world-class achievements. These include liver transplantation, pancreatic cancer surgery, craniofacial reconstruction, atrial fibrillation care, critical care, and gene therapies for rare diseases. Such accomplishments have positioned Taiwan as a global benchmark for healthcare quality, with several treatment protocols adopted into textbooks and incorporated into revisions of international standard treatment guidelines.

Since its founding in 1998, IBMI SNQ has completed more than 2,900 cross-disciplinary certifications spanning specialized medical care, clinical services, management, nursing, long-term care, and community services.

ICHOM is an international non-profit organization which defines the outcomes that are most important to patients. Its Accreditation program is designed to recognize institutions that are leading the way in outcomes measurement and value-based healthcare transformation. Accreditation not only highlights excellence in clinical performance but also fosters transparency, patient-centered care, and continuous improvement. As part of this partnership, IBMI will promote the ICHOM Accreditation program throughout the country.

IBMI SNQ has played a pivotal role in advancing healthcare quality across the Asia-Pacific region as it fostered dialogues among distinguished leaders and institutions. Notable participants include Dr. David Bates, member of the Board of Experts for Newsweek World’s Best Hospitals 2025, and Jennifer L. Bright, President and CEO of ICHOM, together with representatives from renowned organizations such as the University of Tokyo Hospital, Singapore General Hospital, Stanford University, the European Union of Private Hospitals, the World Medical Association, and leading medical centers in Taiwan.

About IBMI SNQ

The Institute for Biotechnology and Medicine Industry (IBMI) administers the Symbol of National Quality (SNQ) Certification Program, Taiwan’s original healthcare quality evaluation system. Since 1998, SNQ has certified thousands of healthcare services and innovations and recognized world-leading medical teams through its rigorous outcome-oriented evaluation standards.


Contact details:

Joy Wan, IBMI SNQ
Email: [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 17:10
Galderma Group AG

Galderma Welcomes Increased Equity Investment From L’Oréal

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.